Skip to content
OpenCapital
Get started

Denali Therapeutics Inc. DNLI Business Segments — Personnel related research and development expenses

Similar metrics at other companies

Arcutis Biotherapeutics, Inc. logo
ARQTReportable Segment — Research and development compensation and personnel-related expenses
$11.05M+14.6%
Tyra Biosciences, Inc. logo
TYRAPersonnel Costs — Research And Development Expense
$11.79M+46.9%
Dianthus Therapeutics logo
DNTHPersonnel And Related Costs — Research And Development Expense
$8.64M+47.7%
Beam Therapeutics logo
BEAMEmployee Related Expenses — Research And Development Expense
$32.87M+12.4%
BioCryst Pharmaceuticals logo
BCRXCompensation and related personnel costs — Research and Development Expense (Excluding Acquired in Process Cost)
$27.09M+119%
Rapport Therapeutics, Inc. logo
RAPPResearch And Development Personnel Related Costs Including Stock-Based Compensation — Research And Development Expense
$10.64M+56.8%

Other financials

Income statement

See full
Revenue-—
Operating income-$137.4M+5.6%
Net income-$128.4M+3.4%
EPS (diluted)-$0.69+11.5%

Balance sheet

See full
Cash & equivalents$390.7M+551%
Total debt$40.0M-22.3%
Total equity$926.1M-17.5%
Total assets$1.3B-0.4%

Cash flow

See full
Operating cash flow-$131.2M+0.2%
CapEx$2.5M-51.4%
Free cash flow-$133.7M+2.1%

Valuation

See full
Market cap$3.93B+54.2%

Profitability

See full
Operating margin-37,938%-37,986pp
Net margin-33,121.9%-33,159pp
FCF margin-31,736.3%-31,830pp

Returns & leverage

See full
Return on equity-49.6%+34.2pp
Debt / equity0×0.0×
Current ratio9.3×-0.3×

Where this comes from

Reported directly by Denali Therapeutics Inc. in its filing.

Tagged under the XBRL concept dnli:PersonnelRelatedResearchAndDevelopmentExpense.

The official record: Denali Therapeutics Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Denali Therapeutics Inc.'s business segments — personnel related research and development expenses.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Denali Therapeutics Inc.'s business segments — personnel related research and development expenses?
Denali Therapeutics Inc. (DNLI) reported business segments — personnel related research and development expenses of $41.83M in Q1 2026.
How has Denali Therapeutics Inc.'s business segments — personnel related research and development expenses changed year-over-year?
Denali Therapeutics Inc.'s business segments — personnel related research and development expenses increased by 3.9% year-over-year, from $40.27M to $41.83M.
What is the long-term trend for Denali Therapeutics Inc.'s business segments — personnel related research and development expenses?
Over 3 years (2022 to 2025), Denali Therapeutics Inc.'s business segments — personnel related research and development expenses has grown at a 5.3% compound annual growth rate (CAGR), from $144.02M to $168.22M.
What does business segments — personnel related research and development expenses mean?
Includes all compensation, benefits, and stock-based compensation for employees directly involved in research and development activities. This metric serves as a proxy for the company's investment in human capital and scientific talent. High levels of these expenses indicate a focus on building internal expertise to drive long-term therapeutic innovation.